(乙基-d5)三苯基鏻溴化物 | 875477-12-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: (乙基-d5)三苯基鏻溴化物
• 英文名称: ethyl-d5-triphenylphosphonium bromide
• 英文别名: (Ethyl-d5)triphenylphosphonium Bromide；1,1,2,2,2-pentadeuterioethyl(triphenyl)phosphanium;bromide
• CAS: 875477-12-6
• 化学式: Br*C₂₀H₂₀P
• 分子量: 376.217
• InChiKey: JHYNXXDQQHTCHJ-LUIAAVAXSA-M

物化性质

• 熔点：
  205 -207°C
• 溶解度：
  可溶于氯仿（少许）、甲醇（少许）

计算性质

• 辛醇/水分配系数(LogP)：
  1.0
• 重原子数：
  22
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  0
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  (乙基-d5)三苯基鏻溴化物 、 邻甲基苄醇 在 potassium tert-butylate 作用下， 以 甲苯 为溶剂， 反应 16.0h， 生成
  参考文献：
  名称：

  Palladium(II)-Catalyzed Aerobic Dialkoxylation of Styrenes:  A Profound Influence of an o-Phenol

  摘要：

  We report a Pd(II)-catalyzed aerobic dialkoxylation of styrene derivatives that requires an o-phenol. Initial scope and preliminary mechanistic studies are presented in which the o-phenol is proposed to facilitate the formation of a quinone methide intermediate.

  DOI：

  10.1021/ja0579053

文献信息

• 2-OXO-1-PYRROLIDINE DERIVATIVES
  申请人：Liu Julie

  公开号：US20110212944A1

  公开（公告）日：2011-09-01

  This invention relates to novel 2-oxo-1-pyrrolidines, their derivatives, and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering a compound with the ability to act as a synaptic vesicle protein 2A (SV2A) ligand and/or a sodium channel blocker.
• [EN] 2-OXO-1-PYRROLIDINE DERIVATIVES<br/>[FR] DERIVES DE 2-OXO-1-PYRROLIDINE
  申请人：CONCERT PHARMACEUTICALS INC

  公开号：WO2010002869A1

  公开（公告）日：2010-01-07

  This invention relates to novel 2-oxo-l -pyrrolidines, their derivatives, and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering a compound with the ability to act as a synaptic vesicle protein 2A (SV2A) ligand and/or a sodium channel blocker.